Cerebrospinal fluid 20-HETE is associated with delayed cerebral ischemia and poor outcomes after aneurysmal subarachnoid hemorrhage

Stroke

Volumn 42, Issue 7, 2011, Pages 1872-1877

  Crago, Elizabeth A ^a   Thampatty, Bhavani P ^a   Sherwood, Paula R ^a   Kuo, Chie Wen J ^a   Bender, Catherine ^a   Balzer, Jeffrey ^b   Horowitz, Michael ^b   Poloyac, Samuel M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

20 HETE; arachidonic acid; delayed cerebral ischemia; fatty acid; neuropsychological outcome; subarachnoid hemorrhage

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN VASOSPASM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DELAYED CEREBRAL ISCHEMIA; DISEASE COURSE; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; NEUROPSYCHOLOGY; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; SUBARACHNOID HEMORRHAGE;

ADOLESCENT; ADULT; AGED; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MALE; MICROCIRCULATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER;

EID: 79960027864     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.605816     Document Type: Article

References (38)

1. Frontera J, Fernandez J, Schmidt M, Claassen J, Wartenberg K, Badjatia N, et al. Defining vasospasm after subarachnoid hemorrhage; what is the most clinically relevant definition? Stroke. 2009;40:1963-1968.
2. Zubkov AY, Rabinstein AA. Medical management of cerebral vasospasm: present and future. Neurol Res. 2009;31:626-631.
3. Laskowitz D, Kolls B. Neuroprotection in subarachnoid hemorrhage. Stroke. 2010;41:S79-S84.
4. Lanterna LA, Lunchi A, Martchenko S, Gritti P, Bonaldi G, Biroli F. Cerebral watershed hypoperfusion in subarachnoid hemorrhage: computed tomography perfusion analysis. J Neurosurg. September 2010;114:961-968.
5. Gordon G, Mulligan S, MacVicar B. Astrocyte control of the cerebrovasculature. GLIA. 2007;55:1214-1221. (Pubitemid 47235363)
6. Losiniecki A, Zuccarello M. Subarachnoid hemorrhage: effect on cerebral blood flow and cerebral metabolism. Front Biosci 2008;1:1845-1856. (Pubitemid 351599737)
7. Kolias AG, Sen J, Belli A. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. J Neurosci Res. 2009;87:1-11.
8. Vergouwen MD, Vermeulen M, van Gihn J, Rinkel G, Wijdicks E, Muizelaar J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group Stroke. 2010;41:2391-2395.
9. Vergouwen MD, Vermeulen M, Roos YB. Delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: is angiographic vasospasm an epiphenomenon? Stroke. 2009;40:e39.
10. Aralasmak A, Akyuz M, Ozkaynak C, Sindel T, Tuncer R. CT angiography and perfusion imaging in patients with subarachnoid hemorrhage: correlation of vasospasm to perfusion abnormality. Neuroradiology. 2009;51:85-93.
11. MacDonald RL, Kassel NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39:3015-3021.
12. Al-Tamimi Y, Orsi N, Quinn A, Homer-Vanniasinkam A, Ross S. A review of delayed ischemic neurologic deficit following aneurysmal subarachnoid hemorrhage: historical overview, current treatment and pathophysiology. World Neurosurg. 2010;73:654-667.
13. Dankbaar J, Rijsdijk M, van der Schaar I, Velthuis B, Wermer M, Rinkel G. Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia artery anuerysmal subarachnoid hemorrhage. Neuroradiology. 2009;51:813-819.
14. Roman R. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131-185. (Pubitemid 34654217)
15. Takeuchi K, Miyata N, Renic M, Harder D, Roman R. Hemoglobin, NO and 20-HETE interactions in medicating cerebral vasoconstriction following SAH. Am J Physiol Reful Integr Comp Physiol. 2006;290:R84-R89.
16. Renic M, Klaus J, OmuraT, Kawashima N, Onishi M, Miyata M, et al. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 2009;29:629.
17. Kehl F, Cambj-Sapunar L, Maier KG, Miyata N, Kametani S, Okamoto H, et al. 20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. Am J Physiol Heart Circ Physiol. 2002;282:1556-1565.
18. Hacein-Bey L, Harder D, Meier H, Varelas P, Miyata N, Lauer K, et al. Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage. AJNR Am J Neuroradiol. 2006;27: 1350-1354. (Pubitemid 44897656)
19. Yu M, Cambj-Sapunar L, Kehl F, Maier K, Takeuchi K, Miyata N, et al. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol. 2004;486:297-306. (Pubitemid 38231060)
20. Poloyac S, Zhang Y, Bies R, Kochanek P, Graham S. Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. J Cereb Blood Flow Metab. 2006;26:1551-1561. (Pubitemid 44809084)
21. Omura T, Tanaka Y, Miyata N, Doizumi C, Sakurai T, Fukasawa M, et al. Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke. 2006;37:1307-1313. (Pubitemid 43731881)
22. Poloyac S, Reynold R, Yonas H, Kerr M. Identification and quantification of the hydroxyeicosatetraenoic acids, 20-HETE and 12-HETE, in the cerebrospinal fluid after subarachnoid hemorrhage. J Neurosci Methods. 2005;144:257-263. (Pubitemid 40720153)
23. Roman RJ, Renci M, Dunn KM, Takeuchi K, Hacein-Bey L. Evidence that 20-HETE contributes to the development of acute and delayed cerebral vasospasm. Neurol Res. 2006;28:738-749. (Pubitemid 44656100)
24. Bolocato C, Frye R, Zemaitis M, Poloyac S. Determination of 20-hydroxyeicosatetraenoic acid in microsmal incubates using highperformance liquid chromatography-mass spectrometry (HPLC-MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2003;794:363-372. (Pubitemid 37101014)
25. Saykin A, Gur R, Gur R, Shtasel D, Flannery K, Mozley L, et al. Normative neuropsychological test performance: effects of age, education, gender and ethnicity. Appl Neuropsychol. 1995;2:79-88.
26. Salinsky M, Storzbach D, Dodrill C, Binder L. Test-retest bias, reliability and regression equations for neuropsychological measures repeated over a 12-16 week period. J Int Neuropsychol Soc. 2001;7:597-605. (Pubitemid 32700954)
27. Levine A, Miller E, Becker J, Seines O, Cohaen B. Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin Neuropsychol. 2004;18:373-384. (Pubitemid 39577274)
28. Blair C. How similar are fluid cognition and general intelligence? A developmental neuroscience perspective on fluid cognition as an aspect of human cognitive ability. Behav Brain Sci. 2006;29:109-125.
29. Segal D, Coolidge F, Cahill B, O'Riley A. Psychometric properties of the Beck Depression Inventory II (BDI-II) among community-dwelling older adults. Behav Modif. 2008;32:3-20.
30. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation. 2005;111:63-69. (Pubitemid 40070845)
31. Ward NC, Tsai I, Barden A, van Bockxmeer F, Puddey I, Hodgson J, et al. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension. 2008;5:1393-1398. (Pubitemid 351555955)
32. Fava C, Montagnana M, Almgren P, Rosberg L, Lippi G, Hedblad B, et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension. 2008;52:373-380.
33. Laffer C, Gainer J, Waterman M, Capdevila J, Laniado-Schwartzman M, Nasjletti A, et al. The T8590C polymorphism of CYP4A11 and 20- hydroxyeicosatetraenoic acid in essential hypertension. Hypertension. 2008; 51:767-772. (Pubitemid 351301533)
34. Takeuchi K, Renic M, Bohman Q, Harder D, Miyata N, Roman R. Reversal of Delayed Vasospasm by an Inhibitor of the Synthesis of 20-HETE. Am J Physiol Heart Circ Physiol. 2005;289:H2203-H2211. (Pubitemid 41507374)
35. Harder D, Gebremedhin D, Narayanan J, Jefcoat C, Falck J, Campbell W, et al. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol. 1994;266:H2098-H2107.
36. Amaral S, Maier K, Schippers D, Roman R, Greene A. CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol. 2004;284:H1528-H1535. (Pubitemid 36460763)
37. Fang X, Faraci F, Kaduce T, Harmon S, Modrick M, Hu S, et al. 20-Hydroxyeicosatetraenoic acid is a potent dilator of mouse artery: role of cyclooxygenase. Am J Physiol Heart Circ Physiol. 2006;291:H2301-H2307.
38. Vergouwen M, Vermeulen M, Coert B, Stroes E, Roos Y. Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab. 2008;28:1761-1770.